 |
||||
 |
|
 |
||
 |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|||||||||||||||||
MONDAY 14 JULYOrganiser: |
Professor Catherine Marchand-Leroux, University Paris 5, France |
Chairs: |
Prof. Catherine Marchand-Leroux University Paris Descartes, France |
| Prof. Csaba Szabo Semmelweis University, Hungary and University of Medicine and Dentistry | |
| of New Jersey, USA | |
9:30 |
Nitric Oxide, Nitrosative Stress in the Pathogenesis of Diabetic Complications |
| Professor Csaba Szabo, Semmelweis University, Hungary and University of Medicine and Dentistry of | |
| New Jersey, USA | |
10:00 |
Elevated talk: Nitric oxide-dependent oxidative changes in skeletal muscles from rats |
| submitted to intestinal ischemia and reperfusion | |
| Mrs Simone Bolonheis University of São Paulo, Brazil | |
10:15 |
Modulation of NO Production by Tyrosine Phosphatase Inhibition in Cardiovascular Diseases |
| Professor Vincent Richard, Rouen University Hospital, France | |
10:45 |
Coffee break |
11:15 |
Nitrosative Stress and Circulatory Shock |
| Professor Salvatore Cuzzocrea, University of Messina, Italy | |
11:45 |
Elevated talk: Pharmacological induction of heme oxygenase-1 protects hippocampal |
| interneurons and inhibits inducible nitric oxide synthase following cerebral ischemia | |
| reperfusion injury | |
| Dr Carmen Mazzola University of Catania, Italy | |
12:00 |
Nitric oxide/nitrosative stress and PARP cascade in acute brain Injuries |
| Dr Valerie Besson, University Paris Descartes, France | |
12:00 |
End of symposium |
Organisers: |
Dr Eamonn Kelly, University of Bristol, UK |
| Professor Graeme Henderson, University of Bristol, UK | |
09:30 |
The multi-dimensional nature of efficacy |
|
|
Prof. Philip G Strange, University of Reading, UK |
10:00 |
Elevated talk: Functional selectivity at the human sphingosine-1-phosphate type 3 receptor |
|
|
Dr Astrid E. Alewijnse, Academic Medical Center, The Netherlands |
10:15 |
New parameters for functional pharmacology – from specific-drug pharmacology to |
| new drug-specific pharmacology? | |
|
|
Prof. Michael Spedding, Institut de Recherche Servier, France |
10:45 |
Coffee break |
11:15 |
Functional selectivity in GPCR desensitization |
| Dr Chris P Bailey, University of Bath, UK | |
11:45 |
Elevated talk: Ability of beta-2 adrenoceptor ligands to selectively induce receptor mediated |
| cAMP formation and ERK phosphorylation | |
| Prof. Ozlem Ugur, Ankara University, Turkey | |
12:00 |
Pathway specific pharmacology of beta-adrenoceptor ligands |
| Prof. Steve Hill, University of Nottingham, UK | |
12:30 |
End of symposium |
Organiser: |
Dr Jean-Pierre Valentin, AstraZeneca, UK |
9:30 |
Non-Clinical Strategies to address QT Liability and Proarrhythmic Risk |
| Dr Chris Pollard, AstraZeneca, UK | |
10:00 |
Value of non-clinical QT-related assays to support drug discovery, development |
| and regulatory approval: case studies | |
| Dr Jean-Pierre Valentin, AstraZeneca, UK | |
10:30 |
The thorough QT study: A review three years after its implementation |
| Dr Borje Darpo, Consultant, Sweden | |
11:00 |
Coffee break |
11:15 |
Drug Induced QT Shortening - Is it an Issue? |
| Dr Rashmi Shah, Independent Pharmaceutical Consultant, Gerrards Cross, UK | |
11:45 |
Elevated talk: Artificial neural network for automatic detection of arrhythmia from |
| electrocardiogram | |
| Dr Mohamed Morsy, El Minia University, Egypt | |
12:00 |
Integrated Risk Assessment and Predictive Value to Humans of Non-Clinical Repolarisation |
| Assays | |
| Dr Rob Wallis, Pfizer, UK | |
12:30 |
End of symposium |
Organisers: |
Professor Ulf Simonsen, University of Aarhus, Denmark |
| Dr Michel Félétou, Institut de Recherche Servier, France | |
Chairs: |
Prof. Ulf Simonsen University of Aarhus, Denmark |
| Dr Michel Félétou, Institut de Recherche Servier, France | |
9:30 |
K+ Channels and Release of EDHF |
| Dr Gillian Edwards, University of Manchester, UK | |
10:00 |
Elevated talk: Role of calcium-activated potassium channels with small and intermediate |
| conductance in bradykinin-induced release of NO in porcine retinal arterioles | |
| Dr Thomas Dalsgaard, University of Aarhus, Denmark | |
10:15 |
Endothelial KCa-channels, EDHF-signalling, and arterial blood pressure |
| Dr Ralf Köhler, Philipps-Universitat, Germany | |
10:45 |
Coffee break |
11:15 |
K+ Channels and Release of Nitric Oxide |
| Dr Edgaras Stankevicius, University of Aarhus, Denmark | |
11:45 |
Elevated talk: Evidence in favour of an intermediate-conductance calcium-activated potassium |
| channel in cortical astrocytes | |
| Mr Thomas Longden, University of Manchester, UK | |
12:00 |
K+ Channels and Endothelial Dysfunction - Therapeutic Option? |
| Dr Michel Félétou, Institut de Recherche Servier, France | |
12:30 |
End of symposium |
THE EUROPEAN HISTAMINE RESEARCH SOCIETY (EHRS) SYMPOSIUM
Organiser: |
Dr Paul Chazot, University of Durham, UK |
| Dr Ekaterini Tiligada, University of Athens, Greece | |
Chairs: |
Professor Steve Hill, University of Nottingham, UK |
| Professor Robin Ganellin, University College, UK | |
9:30 |
Histamine H3 Receptors in Psychiatric Diseases and Parkinson’s Disease |
| Dr. Congyu Jin, University of Helsinki, Finland | |
10:00 |
Elevated talk: Effect of the H4R Antagonist JNJ7777120 on the Cartilage Histamine Content |
| in Rats with Adjuvant Arthritis | |
| Ms Evangelia Zampeli, University of Athens, Greece | |
10:15 |
Histamine Receptors: From the Human Genome to the New Therapeutic Options for Inflammatory |
| Disorders | |
| Professor Rob Leurs, Vrije Universiteit Amsterdam, The Netherlands | |
10:45 |
Coffee break |
11:15 |
The H4 Receptor and Potential Cancer Therapy |
| Dr Robert Kiss, Semmelweis University, Hungary | |
11:45 |
Elevated talk: The H4 histamine receptor is functionally expressed on neurons in the |
| mammalian CNS | |
| Dr Paul Chazot, University of Durham, UK | |
12:00 |
Histamine H3 Receptor Antagonists: From Target Identification to Clinical Candidate |
| Professor Nicholas Carruthers, Johnson & Johnson, USA | |
12:30 |
End of symposium |
| Supported by Johnson & Johnson, USA | |
